pubmed.ncbi.nlm.nih.gov

Sweet taste receptor inhibitors: Potential treatment for equine insulin dysregulation - PubMed

  • ️Mon Jan 01 2018

Sweet taste receptor inhibitors: Potential treatment for equine insulin dysregulation

Melody Anne de Laat et al. PLoS One. 2018.

Abstract

Hyperinsulinemia is a major risk factor for equine laminitis, a debilitating and painful foot condition. Sweet taste receptor (T1R2/3) inhibitors have been used to reduce the insulin and glucose responses to oral carbohydrates in other species. However, their effect in horses has not been investigated. It would be useful to be able to attenuate the large post-prandial insulin response that typically occurs when a carbohydrate-rich meal is fed to insulin-dysregulated horses. Here we have determined the efficacy of two T1R2/3 inhibitors, lactisole and Gymnema sylvestre, for reducing glucose uptake by the equine small intestine in vitro; and post-prandial insulin secretion in ponies in vivo, following a carbohydrate-based meal. We used gas chromatography-mass spectrometry to measure 2-deoxyglucose uptake by explants of small intestine, in the presence and absence of the T1R2/3 inhibitors. Lactisole and G sylvestre reduced 2-deoxyglucose uptake by the intestinal explants by 63% (P = 0.032) and 73% (P = 0.047), respectively, compared to control samples. The study in vivo investigated the effect of the inhibitors on the blood glucose and serum insulin responses to a meal containing D-glucose. Three doses of each inhibitor were tested using a Latin square design, and each dose was compared to a meal with no inhibitor added. Lactisole had no effect on glucose and insulin concentrations, whereas G sylvestre was partially effective at reducing post-prandial blood glucose (by ~10%) and serum insulin concentrations (~25%) in seven ponies, with a most effective dose of 10 mg/kg bodyweight. These data provide preliminary support that T1R2/3 inhibitors may be a useful therapeutic strategy for the management of equine insulin dysregulation and the prevention of laminitis. However, further optimisation of the dose and delivery method for these compounds is required, as well as a direct investigation of their activity on the equine sweet taste receptor.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Glucose uptake by the small intestine in vitro was inhibited by T1R2/3 antagonists.

The mean (± s.e.m.) uptake of 2-deoxyglucose by equine small intestinal tissue (positive control, white bar) following short-term incubation was reduced by 63% (*, P = 0.032) by the addition of 5 mM lactisole (grey bar), and by 73% (**, P = 0.047) by 0.3 mg/mL Gymnema sylvestre (black bar). *P < 0.05.

Fig 2
Fig 2. Gymnema sylvestre reduced the blood glucose and serum insulin responses in seven ponies.

The mean (± s.e.m.) glucose Cmax (A) was not reduced when G sylvestre was added to a D-glucose meal at any dose rate tested. The mean (± s.e.m.) glucose AUC0-360 min (B) decreased with the addition of G sylvestre at 3 and 10 mg/kg BW, compared to no added drug. Similarly, the mean (± s.e.m.) insulin Cmax (C) decreased when G sylvestre was added to a D-glucose meal at 3 and 20 mg/kg, with no decrease at 10 mg/kg, compared to no added drug. Further, the insulin AUC0-360 min (D) decreased when 10 and 20 mg/kg BW G sylvestre was added. The data for each pony is represented with a different symbol.

Fig 3
Fig 3. Gymnema sylvestre did not appreciably reduce aGLP-1 or GIP secretion in response to a carbohydrate meal in seven ponies.

Neither the mean (± s.e.m.) AUCaGLP-1 (A) nor the mean (± s.e.m.) AUCGIP (B) were decreased (P = 0.075 and P = 0.11, respectively) when G sylvestre was added to a D-glucose meal at a dose rate of 10 mg/kg BW.

Similar articles

Cited by

References

    1. Pollitt CC. Equine laminitis. Clinical Techniques in Equine Practice. 2004;3(1):34–44. PubMed PMID: CABI:20053021958.
    1. de Laat MA, McGowan CM, Sillence MN, Pollitt CC. Equine laminitis: Induced by 48 h hyperinsulinaemia in Standardbred horses. Equine Veterinary Journal. 2010;42(2):129–35. doi: 10.2746/042516409X475779 PubMed PMID: ISI:000274410200007. - DOI - PubMed
    1. Johnson PJ, Messer NT, Slight SH, Wiedmeyer C, Buff P, Ganjam VK. Endocrinopathic laminitis in the horse. Clinical Techniques in Equine Practice. 2004;3(1):45–56. PubMed PMID: CABI:20053021959.
    1. de Laat MA, McGree JM, Sillence MN. Equine hyperinsulinemia: investigation of the enteroinsular axis during insulin dysregulation. American Journal of Physiology—Endocrinology and Metabolism. 2016;310(1):E61–E72. Epub Nov 3, 2015. doi: 10.1152/ajpendo.00362.2015 - DOI - PubMed
    1. Geor RJ, Harris P. Dietary Management of Obesity and Insulin Resistance: Countering Risk for Laminitis. Veterinary Clinics of North America-Equine Practice. 2009;25(1):51–65. doi: 10.1016/j.cveq.2009.02.001 PubMed PMID: ISI:000265278100005. - DOI - PubMed

Publication types

MeSH terms

Substances

Grants and funding

Funded by Queensland University of Technology Bluebox: No role in the study. Australian Research Council; DE140100135, no role in the study.